RxDoctor Payments Data

Gary Reiss, MD

Gastroenterology · Marrero, LANPI 1568666543

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $52,520 of the $72,176 with a category attached, or 72.8%. 41 manufacturers reported payments, led by Covidien LP at 45.0% of the total. Reporting peaked in 2019 at $26,958 and has fallen 92.6% since, to $1,988 in 2025. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$72,176in general payments, 2019–2025

Across 476 payments — averaging $151.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Covidien LP$33K
  • GI Supply, Inc.$17K
  • Medtronic$9K
  • Micro-tech Endoscopy USA, Inc.$4K
  • Boston Scientific$3K
  • AbbVie$2K
  • plus $5K from 35 others
$9,926,963in research payments, 2019–2025

Across 2,420 payments — averaging $4102.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2.3M
  • Intercept Pharmaceuticals, Inc.$1M
  • Alnylam Pharmaceuticals Inc.$794K
  • Ironwood Pharmaceuticals, Inc$669K
  • Vanda Pharmaceuticals Inc.$620K
  • Regeneron$587K
  • plus $3.9M from 24 others

What the payments were for

  • Consulting fees$9,10013%
  • Speaking & faculty fees$52,52073%
  • Food & beverage$10,55615%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,176 in reported general payments places this provider in the 90th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$95,369
Medicare patients
313
Services billed
871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide113$113,070
ClenpiqSod Picosulf/Mag Ox/Citric Ac204$34,036
CreonLipase/Protease/Amylase17$25,560
RelistorMethylnaltrexone Bromide11$25,154
TrulancePlecanatide23$24,105
Omeprazole404$6,994
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates75$4,683
Dicyclomine Hcl284$4,046
Pantoprazole Sodium352$3,146
SutabSod Sulf/Pot Chloride/Mag Sulf18$2,980
Ondansetron OdtOndansetron126$2,733
Esomeprazole Magnesium58$2,269
Promethazine Hcl106$1,924
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag14$1,760
Famotidine104$1,548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,834$138,629130 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor, Trulance$228$49,25934 claims
Braintree Laboratories, Inc.Sutab, Suflave$14$4,74032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →